IMPORTANT INFORMATION
Specimens and Orders for RespriDx® Are No Longer Being Accepted
RespriDx® utilizes PathFinderTG®, a proprietary DNA-based diagnostic molecular testing platform used by Interpace Diagnostics® to identify tumor suppressor gene and oncogene mutations within their GI (PancraGEN® and BarreGEN®) and non-thyroidal (RespriDx®, Tissue Identity) testing services.
Novitas Solutions, the Medicare Administrative Contractor for Interpace, has issued a Local Coverage Decision (L39365) that ended reimbursement for PancraGEN®.
PancraGEN comprised the vast majority of GI-related and non-thyroidal testing within Interpace. Because PancraGEN was primarily ordered for Medicare patients, this change in the reimbursement policy means that Interpace Diagnostics can no longer support utilization of the PathFinderTG® platform and testing of specimens with RespriDx.
Specimens and orders for RespriDx are no longer being accepted as of
May 30, 2025*
Interpace will continue to offer ThyGeNEXT®+ThyraMIR®v2 without interruption.
Questions regarding this announcement can be addressed by contacting Interpace Client Services.
(800) 495‑9885 or clientservices@interpace.com
*The last shipping date using FedEx Priority Overnight is Thursday May 29th (ensure the FedEx pickup time cutoff is met).
